Just a few years since pioneering a Covid-19 vaccine, Moderna faces a hostile political environment and a looming patent ...

The personalized cancer vaccine market is gaining rapid momentum, driven by biotech advancements and rising demand for targeted immunotherapies. The new 2025 report analyzes key players like BioNTech, ...

HHS cites need for review due to 'oversight' issues CDC states low risk of H5 bird flu to public Moderna's shares drop 5.5% Feb 26 (Reuters) - U.S. health officials are reevaluating a $590 million ...

Citi analyst Geoff Meacham reiterated a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $40.00. The ...

"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna.

Vaccine makers Moderna Inc (NASDAQ:MRNA) and Novavax Inc (NASDAQ:NVAX) are facing selling pressure on Wednesday following reports suggesting the Trump administration will end support for Gavi.

The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in the waning days of the Biden administration. “While it is crucial that ...

(Bloomberg) -- US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to Moderna Inc., people familiar with the matter said.

The Department of Health and Human Services is reevaluating a $590 million contract for avian influenza mRNA vaccines that the prior administration struck with Moderna, Bloomberg first reported on ...

Trump Administration Weighs Pulling Funding for Moderna Bird Flu Vaccine, Bloomberg News Reports (Reuters) - U.S. health officials are reevaluating a $590 million contract that was awarded to ...